The ongoing debate surrounding prescription drug pricing continues as pharmaceutical companies and pharmacy benefit managers (PBMs) remain exempt from disclosing actual prices paid for...
The Trump administration’s proposed rule leaves pharmaceutical companies and pharmacy benefit managers (PBMs) without a requirement to disclose the actual prices paid for prescription...